Understanding Immunogenicity in Biopharmaceuticals
Immunogenicity remains a central consideration in biopharmaceutical development, even as biologics and advanced therapies continue to expand across therapeutic areas. Its impact extends beyond safety, influencing efficacy, dosing durability, and long-term treatment outcomes. From a strategic perspective, proactive immunogenicity management supports patient-centric development, reduces late-stage clinical risk, and enables broader market access. This is especially […]